Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials - 27/09/17
Doi : 10.1016/j.jaci.2016.12.953
Carlos Iribarren, MD, MPH, PhD a, Kenneth J. Rothman, DrPH b, Mary S. Bradley, MS c, Gillis Carrigan, PhD c, Mark D. Eisner, MD c, Hubert Chen, MD, MPH c 
a Division of Research, Kaiser Permanente Medical Care Program, Oakland, Calif
b RTI Health Solutions, Research Triangle Park, NC
c Genentech, Inc, South San Francisco, Calif
| The study was funded by Genentech, Inc, South San Francisco, California, and Novartis Pharma AG, Basel, Switzerland. Medical writing support for this manuscript was provided by Linda Goldstein, PhD, and Charlotte Kenreigh, PharmD, of Excel Scientific Solutions, Southport, Connecticut, and funded by Genentech, Inc, and Novartis Pharmaceuticals Corporation. |
|
| Disclosure of potential conflict of interest: C. Iribarren has received fees as a member of the EXCELS Advisory Board from Genentech. K. J. Rothman has received payment for writing or reviewing the manuscript from RTI International. M. S. Bradley was employed by Genentech at the time of the study and holds stock options from Roche. G. Carrigan and H. Chen are employed by Genentech and receive stock options from Roche. M. D. Eisner is employed by Genentech/Roche. |
© 2017
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 139 - N° 5
P. 1678-1680 - mai 2017 Retour au numéro
Article précédent
- Could daratumumab be used to treat severe allergy?
- Mark A. Blankestijn, Niels W.C.J. van de Donk, Kate Sasser, André C. Knulst, Henny G. Otten
- Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab
- Donald W. MacGlashan, Sarbjit S. Saini
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?